The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 348:259-260 January 16, 2003 Number 3
NextNext

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Fried, M. W.
-PubMed Citation
To the Editor: Fried et al. (Sept. 26 issue)1 compared three treatment regimens in terms of sustained virologic response in patients with chronic hepatitis C virus (HCV) infection; the regimens were peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone. Naturally, the patients receiving peginterferon alfa-2a plus ribavirin had the highest rate of sustained virologic response. In the community, the current treatment of choice is peginterferon alfa-2b with ribavirin. Thus, this study did not compare the newer regimen, peginterferon alfa-2a with ribavirin, with the best therapy currently available. The rate of sustained virologic response of 56 percent . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.